Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer

OBJECTIVE: The aim of the present study was to assess patient compliance with tyrosine kinase inhibitor (TKI) treatment used for refractory and progressive thyroid cancer, in addition to the efficacy and serious adverse events associated with these agents. METHODS: We retrospectively analyzed data f...

Descripción completa

Detalles Bibliográficos
Autores principales: Chrisoulidou, Alexandra, Mandanas, Stylianos, Margaritidou, Efterpi, Mathiopoulou, Lemonia, Boudina, Maria, Georgopoulos, Konstantinos, Pazaitou-Panayiotou, Kalliopi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562763/
https://www.ncbi.nlm.nih.gov/pubmed/26366098
http://dx.doi.org/10.2147/OTT.S86322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562763/
https://www.ncbi.nlm.nih.gov/pubmed/26366098
http://dx.doi.org/10.2147/OTT.S86322

Ejemplares similares